<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176406</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00065334_1</org_study_id>
    <nct_id>NCT04176406</nct_id>
  </id_info>
  <brief_title>Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)</brief_title>
  <acronym>MCI_Sub</acronym>
  <official_title>Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an administrative supplement to an existing project &quot;Using fMRI-guided TMS to&#xD;
      increase central executive function in older adults: NCT02767323&quot; This award allows extending&#xD;
      our existing fMRI-TMS paradigm to patients with a prodromal form of Alzheimer's Disease (AD)&#xD;
      known as amnestic Mild Cognitive Impairment (MCI), and investigate the role of brain health&#xD;
      factors in mediating the TMS-related memory performance benefits associated with&#xD;
      communication between a network of frontoparietal brain regions in these populations.&#xD;
&#xD;
      The focus on focal neurostimulation at only a single site represents a fundamental gap in the&#xD;
      approach of memory-based neurostimulation therapies. Neurostimulation affects multiple sites&#xD;
      within a cortical network, but these global effects have not been used as targets for&#xD;
      stimulation because of limited knowledge about what influence these localized sites have on&#xD;
      global changes in brain state. To address this problem, multimodal neuroimaging tools and&#xD;
      network modeling approaches developed though the parent U01 project will be used, to&#xD;
      demonstrate how focal neurostimulation improves the efficacy of TMS for enhancing memory&#xD;
      function. These goals will be addressed in the Administrative Supplement under our two&#xD;
      specific aims. First, network-guided TMS will be applied to optimize memory success based in&#xD;
      the frontoparietal network (FPN) in a new group of MCI patients. A new form of TMS targeting&#xD;
      that involves modeling of the global network to understand how the controllability of a&#xD;
      stimulation site evokes changes in widespread brain networks will be tested. Second,&#xD;
      structural and functional factors affecting the efficacy of individualized network-guided TMS&#xD;
      will be identified to ameliorate deficits in MCI. By creating a multimodal model of neural&#xD;
      deficits related to MCI, network-guided TMS will be adjusted to demonstrate how the MCI brain&#xD;
      might compensate for these neural deficits. The parent U01 project has made foundational&#xD;
      advances towards these goals, as we have demonstrated the ability of to selectively enhance&#xD;
      and reduce working memory performance in healthy older adults. In the current Administrative&#xD;
      Supplement this paradigm will be extended to a group of MCI participants in order to test the&#xD;
      hypothesis that excitatory rTMS to the working memory network can provide positive outcomes&#xD;
      for patients with pre-clinical AD. The proposed work will provide an important tool for&#xD;
      studying the stability and controllability of network connectivity of memory states in the&#xD;
      aging brain, as well as new information on the effectiveness of brain stimulation&#xD;
      technologies as a therapeutic approach for cognitive decline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Covid-19, Funding ended&#xD;
  </why_stopped>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Accuracy (in Percentage)</measure>
    <time_frame>Through study completion, an average of one year</time_frame>
    <description>Accuracy (in percentage) will be assessed to evaluate the acute effect of rTMS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Reaction Times (ms)</measure>
    <time_frame>Through study completion an average of one year</time_frame>
    <description>Reaction times (in ms) will be assessed to evaluate the acute effect of rTMS</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>rTMS over a node within the fronto-parietal network</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS over a node within the fronto-parietal network</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>electrical sham coil applied over a node within the fronto-parietal network.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS over the DLPFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS over the DLPFC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>electrical sham coil applied over the DLPFC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>excitatory 5Hz rTMS will be used</description>
    <arm_group_label>rTMS over a node within the fronto-parietal network</arm_group_label>
    <arm_group_label>rTMS over the DLPFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
    <arm_group_label>Sham rTMS over a node within the fronto-parietal network</arm_group_label>
    <arm_group_label>Sham rTMS over the DLPFC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English Speaking&#xD;
&#xD;
          -  willing to provide consent&#xD;
&#xD;
          -  signed HIPAA authorization&#xD;
&#xD;
          -  clinical consensus for MCI; and/or met inclusion criterial on MoCA, ApoE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any I DSM IV disorder that is unstable or untreated&#xD;
&#xD;
          -  current or past history of substance abuse or dependence (excluding nicotine)&#xD;
&#xD;
          -  women who are pregnant or breast feeding&#xD;
&#xD;
          -  intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants,&#xD;
             or electrodes&#xD;
&#xD;
          -  increased risk of seizure for any reason, including prior diagnosis of epilepsy,&#xD;
             seizure disorder, increased intracranial pressure, or history of significant head&#xD;
             trauma greater than mild concussion (History of significant head trauma, including&#xD;
             with loss of consciousness for â‰¥ 30 minutes, alteration of consciousness for up to 24&#xD;
             hours following the event, or post-traumatic amnesia) in the past 10yrs or head injury&#xD;
             received after age 65&#xD;
&#xD;
          -  Neurological disorder including, but not limited to: space occupying brain lesion; any&#xD;
             history of seizures, history of cerebrovascular accident; cerebral aneurysm ,&#xD;
             Dementia, Huntington chorea, multiple sclerosis&#xD;
&#xD;
          -  Increased risk of seizure for any reason, including prior diagnosis of increased&#xD;
             intracranial pressure (such as after large infarctions or trauma), or currently taking&#xD;
             medication that are on the strong potential hazard list for rTMS.&#xD;
&#xD;
          -  Subjects taking medications with an ACB score of 3.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence G Appelbaum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>December 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04176406/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study was terminated prior to application of rTMS or Sham.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rTMS Over a Node Within the Fronto-parietal Network</title>
          <description>excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.&#xD;
rTMS: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="P2">
          <title>Sham rTMS Over a Node Within the Fronto-parietal Network</title>
          <description>electrical sham coil applied over a node within the fronto-parietal network.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
        <group group_id="P3">
          <title>rTMS Over the DLPFC</title>
          <description>excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.&#xD;
rTMS: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="P4">
          <title>Sham rTMS Over the DLPFC</title>
          <description>electrical sham coil applied over the DLPFC.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These participants only performed the behavioral task. No TMS was applied.</population>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Participants</title>
          <description>The following numbers represent the baseline characteristics for the participants enrolled in the study, who performed only the behavioral task. None of these participants received rTMS</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Accuracy (in Percentage)</title>
        <description>Accuracy (in percentage) will be assessed to evaluate the acute effect of rTMS.</description>
        <time_frame>Through study completion, an average of one year</time_frame>
        <population>The study had to be interrupted because of Covid-19 situation, while we were still piloting the behavioral task. Therefore no data with rTMS were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham rTMS Over the DLPFC</title>
            <description>electrical sham coil applied over the DLPFC.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Accuracy (in Percentage)</title>
          <description>Accuracy (in percentage) will be assessed to evaluate the acute effect of rTMS.</description>
          <population>The study had to be interrupted because of Covid-19 situation, while we were still piloting the behavioral task. Therefore no data with rTMS were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Reaction Times (ms)</title>
        <description>Reaction times (in ms) will be assessed to evaluate the acute effect of rTMS</description>
        <time_frame>Through study completion an average of one year</time_frame>
        <population>The study had be be terminated early due to the Covid-19 situation, while we were still piloting the behavioral task. Therefore no participants received rTMS</population>
        <group_list>
          <group group_id="O1">
            <title>rTMS Over a Node Within the Fronto-parietal Network</title>
            <description>excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.&#xD;
rTMS: excitatory 5Hz rTMS will be used</description>
          </group>
          <group group_id="O2">
            <title>Sham rTMS Over a Node Within the Fronto-parietal Network</title>
            <description>electrical sham coil applied over a node within the fronto-parietal network.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
          </group>
          <group group_id="O3">
            <title>rTMS Over the DLPFC</title>
            <description>excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.&#xD;
rTMS: excitatory 5Hz rTMS will be used</description>
          </group>
          <group group_id="O4">
            <title>Sham rTMS Over the DLPFC</title>
            <description>electrical sham coil applied over the DLPFC.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Reaction Times (ms)</title>
          <description>Reaction times (in ms) will be assessed to evaluate the acute effect of rTMS</description>
          <population>The study had be be terminated early due to the Covid-19 situation, while we were still piloting the behavioral task. Therefore no participants received rTMS</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event data are collected during rTMS and a few minutes after.</time_frame>
      <desc>rTMS was not applied so no adverse event/ all cause mortality were monitored</desc>
      <group_list>
        <group group_id="E1">
          <title>rTMS Over a Node Within the Fronto-parietal Network</title>
          <description>excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.&#xD;
rTMS: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="E2">
          <title>Sham rTMS Over a Node Within the Fronto-parietal Network</title>
          <description>electrical sham coil applied over a node within the fronto-parietal network.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
        <group group_id="E3">
          <title>rTMS Over the DLPFC</title>
          <description>excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.&#xD;
rTMS: excitatory 5Hz rTMS will be used</description>
        </group>
        <group group_id="E4">
          <title>Sham rTMS Over the DLPFC</title>
          <description>electrical sham coil applied over the DLPFC.&#xD;
Sham rTMS: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lawrence G. Appelbaum</name_or_title>
      <organization>Duke University</organization>
      <phone>919-613-7664</phone>
      <email>greg@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

